DTIL · Precision BioSciences

The thesis

Precision BioSciences' hepatitis B gene-editing data held up when presented in full, but the shares are more likely to lag the S&P 500 over the next three months. No hepatitis B result is due before Phase 2 dosing, which the company guides for the first quarter of 2027. The next dated test is the Duchenne muscular dystrophy safety data guided for year-end 2026.

The rating is Low because the price already reflects the data and the calendar holds little before 2027. The shares closed at $9.15 on 11 November 2026, above the $7.75 price of the 5 November 2026 offering. That close is 19.0% below the 52-week intraday high of $11.29 set on 5 November 2026, the day the data and the offering came out.

The core finding is still two paired liver biopsies at the 0.4 mg/kg dose. They showed reductions of about 1 log (10-fold) and 1.5 log (35-fold) in covalently closed circular DNA (cccDNA), the virus's persistent reservoir inside liver cells. Two patients are too few to size the effect, so the biopsy case depends on the Phase 2 study.

Bullish and bearish views on Precision BioSciences, Inc.

The bull case on Precision BioSciences, Inc. (DTIL), in brief: a second biopsy replicated the first. The bear case: new stock was priced below the market.

Bull case

• A second biopsy replicated the first. The company's 5 November 2026 AASLD release reports paired biopsies from two patients at 0.4 mg/kg, with cccDNA reductions of about 1 log and 1.5 log. Before that, the case rested on a single 1-log biopsy reported on 27 May 2026.
• Viral RNA cleared and stayed cleared. The same release reports that 11 of 12 evaluable patients (92%) with detectable baseline pregenomic RNA (pgRNA) reached undetectable levels, including all six at 0.4 mg/kg. pgRNA is a blood marker of cccDNA activity, and every patient with at least six months of follow-up stayed undetectable.
• The chosen dose looks clean so far. At 0.4 mg/kg the company reported no serious adverse events and no Grade 3 or higher hypotension across 15 administrations in eight patients. It reported no dose-limiting toxicities across 59 administrations in 25 patients at the 28 September 2026 data cutoff.
• Cash now reaches late 2029. The 5 November 2026 offering raised about $125 million in expected gross proceeds, and the company guides cash into the fourth quarter of 2029 (8-K, 9 November 2026). The pricing release names First Light Asset Management, MPM BioImpact, Lynx1 Capital Management, Readout Capital and Driehaus Capital Management among the buyers.
• Duchenne dosing can continue. Benzinga reported on 5 November 2026 that a safety board cleared further dosing in the Phase 1/2 PBGENE-DMD trial after no serious adverse events in the first patient.
• Directors bought in September. SEC Form 4 filings show three directors buying in the open market: Geno Germano 2,609 shares at $6.28 and Melinda Brown 1,135 shares at $6.27 on 25 September 2026, and Stanley Frankel 1,000 shares at $6.00 on 28 September 2026.

Bear case

• New stock was priced below the market. The 5 November 2026 offering sold 10,235,077 common shares at $7.75, plus pre-funded warrants for up to 5,893,964 shares at a $0.000005 exercise price. Those buyers paid less than the $9.15 close of 11 November 2026.
• The share count keeps growing. Panabee's summary of the third-quarter report, published 3 November 2026, shows about 27.9 million common shares outstanding at 30 September 2026. That count was up 16% since the start of 2026, with $11 million raised through the at-the-market equity facility before the November offering added its shares and warrants.
• Surface antigen fell but was not cleared. A functional hepatitis B cure is usually defined as sustained loss of hepatitis B surface antigen (HBsAg). The 5 November 2026 release reports HBsAg reductions in all 24 evaluable patients, with a maximum reduction of about 94% at 0.4 mg/kg.
• A liver-enzyme signal appeared at the chosen dose. The release reports one delayed rise in the liver enzymes alanine and aspartate aminotransferase (ALT/AST), peaking at 306/278 U/L at 0.4 mg/kg. It resolved without intervention.
• The hepatitis B calendar is empty for months. The company guided on 5 November 2026 for ELIMINATE-B2 Phase 2 dosing to start in the first quarter of 2027, with initial open-label results in the second half of 2027.

Price setup

The shares closed at $9.15 on 11 November 2026, down from $10.60 on 6 November 2026, the highest close of the post-data run. They had closed at $8.12 on 4 November 2026, the session before the AASLD data and the offering. The 52-week intraday high is $11.29, set on 5 November 2026.

The 3-month change is 25.3%, measured from a $7.30 close on 13 August 2026. The last close sits above the 50-day moving average of $7.00 and the 200-day moving average of $6.73, both as of 11 November 2026. The 52-week closing low is $3.57, set on 5 February 2026.

The $7.75 offering price is the main reference level below the market, and the 50-day average sits under it. The shares have given back part of the post-data gain over the four sessions to 11 November 2026 while the offering shares and pre-funded warrants came into the market. Third-quarter results came out on 3 November 2026, so no quarterly report is near.

Catalysts ahead

• ~31 December 2026 (est.): Guided year-end initial PBGENE-DMD safety data. Tests whether Duchenne dosing stays clean beyond the first patient, the only patient described in the safety board's 5 November 2026 clearance.
• ~31 March 2027 (est.): End of the guided first-quarter 2027 window for first ELIMINATE-B2 Phase 2 dosing. Shows whether the hepatitis B program moves on schedule into the global Phase 2 study; a slip would push back the next efficacy readout.
• ~31 December 2027 (est.): Guided second-half 2027 initial open-label ELIMINATE-B2 results. These are the next hepatitis B efficacy data, the first test of whether the biopsy and pgRNA results hold in a larger group.

What would change the view

A daily close above $10.89, over the $10.60 close of 6 November 2026 that topped the post-data run, which would show the shares leading the S&P 500 and prove this call wrong.

What it trades with

The shares move mainly on the company's own hepatitis B and Duchenne news. The 5 November 2026 data and offering set the recent price range, between the $7.75 offering price and the $11.29 intraday high of the same day.

The company sits among small rare-disease and gene-therapy names such as Viridian Therapeutics (VRDN), Xeris Biopharma (XERS) and Disc Medicine (IRON). Those peers do not share its clinical risk, so a stronger group would not offset a safety or timing problem here.

The company raised equity twice in 2026, through the at-the-market facility and the November offering. That makes the shares more sensitive than a fully funded peer to investor appetite for small-cap biotech financing.